Cambridge-based, Airna, a biotech company working on RNA therapeutics to help patients with rare illnesses raised $60 million led by Forbion in the financing round.
The round was actively led by Alexandria Venture Investments, Ono Venture Investment, ND Capital ARCH Venture Partners. After this round, the total funds brought in is $90 million.
Airna $60M Financing Series By Forbion
CEO of Airna, Kris Elverum said that the funds raised will help us to speed up trials and R&D of other products.
Airna is a biotechnology company that develops RNA therapeutics for the advanced treatment of patients with rare diseases.
Co-founders RESTORE+™, Jin Billy Li, and Thorsten Stafforst were the first users of the therapeutic approach for RNA precise editing.
Airna Research Center is situated in Tübingen, Germany. It is an advanced therapeutic program that helps in the treatment of patients that have inherited genetic disease AATD known as alpha-1 antitrypsin deficiency.
Also Read: Pony.ai Invested In Beijing Guangzhou A $140M